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BACKGROUND: Cetuximab enhances the efficacy of chemotherapy in several cancer types. This trial assessed the activity of cetuximab
and chemotherapy in advanced gastric cancer.
METHODS: Patients with previously untreated, metastatic, gastric cancer received cetuximab 400mgm
 2 at first infusion followed
by weekly infusions of 250mgm
 2 combined with FUFOX (oxaliplatin 50mgm
 2, 5-FU 2000mgm
 2, and DL-folinic acid
200mgm
 2 d1, 8, 15 and 22 qd36). The primary endpoint was tumour response.
RESULTS: Overall, 52 patients were enrolled. The most common grade 3/4 toxicities were diarrhoea (33%), and skin toxicity (24%).
Efficacy was evaluable in 46 patients who showed a response rate of 65% (CI 95%: 50–79%) including four complete responses.
Time to progression (TTP) was 7.6 months (CI 95%: 5.0–10.1 months) and overall survival (OS) was 9.5 months (CI 95%: 7.9–11.1
months). Epidermal growth factor receptor (EGFR) was detectable in 60% of tumours but showed no correlation with treatment
outcome. A KRAS mutation was found in only 1 of 32 (3%) tumour samples analysed.
CONCLUSION: Cetuximab plus FUFOX showed an interesting high response rate in metastatic gastric cancer. Cetuximab plus
platinum–fluoropyrimidine chemotherapy is at present being investigated in a phase III randomised controlled trial.
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Stomach cancer is the fourth most common cancer worldwide, with
603003 new cases in men and 330290 new cases in women in
2002 (Kamangar et al, 2006). Although current fluorouracil- and
platinum-based combination chemotherapy regimens confer a
survival benefit to patients with advanced gastric cancer when
compared with the best supportive care (Wagner et al,2 0 0 6 ) ,t h e
outcomes remain suboptimal. Oxaliplatin has been shown to equal
the efficacy of cisplatin in this clinical setting (Al-Batran et al, 2008;
Cunningham et al, 2008). In a previous trial our study group showed
that weekly oxaliplatin plus 5-fluorouracil/folinic acid (FUFOX) has
a high activity and an acceptable toxicity profile when used in
advanced gastric cancer (Lordick et al, 2005). This led to a broad
acceptance of the FUFOX regimen within the Arbeitsgemeinschaft
Internistische Onkologie (AIO) study network and investigators felt
that FUFOX can serve as a chemotherapy backbone for combination
studies with biologically targeted drugs.
Cetuximab is a monoclonal IgG1 antibody directed against the
epidermal growth factor receptor (EGFR) (Martinelli et al, 2009).
Cetuximab binds to the extracellular domain of EGFR in its
inactive configuration and competes for receptor binding by
occluding the ligand-binding region. This antibody–receptor
interaction prevents receptor dimerisation and thereby blocks
ligand-induced EGFR tyrosine kinase activation. Cetuximab also
induces EGFR internalisation, downregulation, and degradation.
Antibody-dependent cytotoxicity may also contribute significantly
to the anticancer activity of cetuximab. By provoking an immune
system mediated antitumour response, cetuximab inhibits
cancer-cell proliferation (G1 phase arrest), angiogenic growth
factor production (VEGF) and tumour-induced angiogenesis, and
cancer cell invasion. In preclinical and clinical tumour models
cetuximab potentiates the antitumour activity of cytotoxic drugs
and radiotherapy (Ciardiello and Tortora, 2008).
In pivotal phase II and phase III studies, cetuximab has shown
activity in chemotherapy refractory and chemo-naı ¨ve-advanced
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scolorectal cancer given in combination with irinotecan- or
oxaliplatin-based chemotherapy (Cunningham et al, 2004;
Bokemeyer et al, 2009; Van Cutsem et al, 2009), which is in
combination with platinum-based chemotherapy in both advanced
non-small-cell lung cancer and squamous cell cancer of the
head and neck (Vermorken et al, 2008) and in combination
with radiotherapy in localised head and neck cancer (Bonner et al,
2006).
Epidermal growth factor receptor has been found to be
overexpressed in gastric cancer (Gamboa-Dominguez et al, 2004;
Dragovich et al, 2006). Although colorectal tumours with an
activating mutation of the Kirsten(K)-ras gene are not sensitive to
EGFR antibodies (Amado et al, 2008; Karapetis et al, 2008), the
incidence of KRAS mutations in gastric cancer appears to be low
(Kim et al, 2003; Lee et al, 2003; Zhao et al, 2004).
We carried out a phase II trial to investigate the activity and
safety of cetuximab plus weekly FUFOX in patients with metastatic
gastric cancer.
PATIENTS AND METHODS
This multicentre study was conducted at seven institutions in
Germany and Austria. It was organised within the study network of
the Arbeitsgemeinschaft Internistische Onkologie (AIO) and was
coordinated by the Munich centre for clinical studies. The protocol
was approved by the ethics committee for human research at the
Technische Universita ¨tM u ¨nchen, Munich, and conformed to the
principles of the Declaration of Helsinki and its subsequent
amendments. The study has been assigned the European Clinical
Trials Database number 2004-004024-12.
Patient characteristics
Eligibility criteria included the following: histologically confirmed
metastatic or locally advanced irresectable adenocarcinoma of the
stomach or oesophago-gastric junction; age 18 years or older;
Eastern Cooperative Oncology Group (ECOG) performance status
p2; X1 unidimensionally measurable lesion X1cm in diameter
detected by computed tomography (CT) scan or magnetic
resonance imaging (MRI); cardiac ejection fraction within normal
limits; absolute neutrophil count X2000ml
 1; thrombocyte count
X100000ml
 1; total bilirubin p1.5 upper limit of normal (ULN)
and transaminases p2.5 ULN; creatinine clearance 470mlmin
 1;
no previous malignancy and no chemotherapy except in the
adjuvant or neoadjuvant setting 46 months before study entry. All
patients gave written informed consent.
Treatment
Cetuximab was administered at an initial dose of 400mgm
 2 on
day 1 over 120min, followed by weekly doses of 250mgm
 2 over
60min. Oxaliplatin 50mgm
 2 was given i.v. over 120min followed
by folinic acid 200mgm
 2 i.v. over 120min and 5-fluorouracil
2000mgm
 2 i.v. over 24h on days 1, 8, 15, and 22, every 5 weeks
(one cycle). Treatment continued until best response, or until there
was evidence of disease progression, unacceptable toxicity, death,
or withdrawal of patient consent. Toxicity was graded according
to the National Cancer Institute Common Toxicity Criteria
(NCI-CTC, version 3.0).
Evaluation
Patients were assessed weekly for potential adverse events and
disease-related signs and symptoms. Patients who had ended their
treatment but had not experienced disease progression were
observed every 12 weeks until progressive disease and every 3
months thereafter. Tumour measurements were undertaken every
two cycles (10 weeks) and were carried out according to Response
Evaluation Criteria in Solid Tumours (RECIST) criteria (Therasse
et al, 2000). Best objective responses (primary study endpoint) and
confirmed responses were reported.
EGFR expression analysis
Before randomisation, EGFR expression was evaluated locally from
tumour specimens using a standardised immunohistochemistry
assay (EGFR pharmDx Dako, Glostrup, Denmark). Positive
staining was defined as any membrane staining above background
level (defined as the level noted in a negative control sample) in
X1% cancer cells of any intensity: with 1þ equating to faint or
barely perceptible membrane staining, 2þ indicating weak to
moderate staining of the complete cell membrane and 3þ
indicating strong staining of the complete cell membrane.
KRAS mutational analysis
Screening of tumour DNA for KRAS mutations in codon 12 or 13
was carried out centrally. Before DNA extraction, tumour tissue
(frozen or paraffin-embedded) was manually microdissected to
assure at least 60% tumour cell content of the analysed sample.
KRAS mutation analysis was carried out by polymerase chain
reaction (PCR) amplification of exon 2 and direct sequencing.
Primers were modified according to Brink et al (2003). DNA
sequencing was carried out using the BigDye Terminator v1.1
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA)
and separation of the products using an automated sequencing
system (3130 Genetic Analyzer, Applied Biosystems).
Statistical analysis
The primary study endpoint was the proportion of patients who
responded to cetuximab–FUFOX. The study was designed as a
two-stage trial assuming a response rate of p30% as not being of
further interest (null hypothesis) and a response rate of X50% as
interesting (alternative hypothesis). The best-observed response
was taken as a basis for the determination of primary endpoint and
confirmed responses were also reported. The statistical analysis
was carried out using SPSS software (version 12.0; SPSS, Chicago,
IL, USA). In all, 95% CIs were calculated for all relevant estimates
using StatXact (version 5; Cytel, Cambridge, MA, USA). All
statistical analyses were carried out at a 5% level of significance.
The secondary study endpoints were median overall survival
(OS), time to progression (TTP), and toxicity. Analysis of TTP and
OS was carried out using the Kaplan–Meier life-table method.
Comparisons between groups of patients were made by log-rank
test. Median survival and hazard ratios (HR) calculated by Cox’s
proportional hazards model were reported, with 95% CIs. TTP and
OS were analysed in the intent-to-treat (ITT) population. Time to
progression was determined from the day of study assignment to
the date of any progression, or last contact. Patients who had not
progressed at the time of the final analysis were censored at the
date of their last tumour assessment. OS was calculated from the
day of assignment to death. Patients alive at the final survival
analysis were censored using the last contact date.
RESULTS
Patient characteristics
A total of 52 patients were enrolled between April 2005 and March
2006. The primary tumour was located at the oesophago-gastric
junction in 25 patients and in other parts of the stomach in the
remaining 27 patients. All patients presented with metastatic
disease, with the lymph nodes, the liver, the peritoneum, and the
lung as the predominant metastatic sites (Table 1).
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In total, 167 cycles of cetuximab–FUFOX were administered, with
a median of two cycles (range 0–8) per patient. The median
duration of treatment was 10 weeks (range 0–48). In all, 132 of 167
cycles (79%) were given without any delay. At least one dose
reduction was carried out in 23 out of 52 patients (44%) because of
adverse events, including reductions for one or both cytotoxic
drugs (oxaliplatin and/or 5-fluorouracil) in 21 out of 52 patients
(40%) and for the antibody cetuximab in 16 out of 52 patients
(31%). The main reasons for dose reductions and delays were
diarrhoea, haematological side effects, skin toxicity, and fatigue–
nausea syndrome.
The study protocol was advised to be continued with treatment
until progression. However, 25 patients (48%) discontinued the
treatment for other reasons. The main reasons for unplanned
therapy discontinuation were as follows: therapy-related adverse
events or the deterioration of performance status in 11 patients
(21%), request of the patient or withdrawal of consent in 7 patients
(13%), achievement of a best clinical response in 3 patients (6%),
secondary resection with no further study treatment after surgery
in 2 patients (4%), and death without documented progression in 2
patients (4%). Five patients (10%) died within 60 days of study
inclusion. The following two deaths were related to treatment: 1
patient died because of a septic shock, which occurred as a result
of neutropenic septic diarrhoea; another patient suffered a severe
infusion-related hypersensitivity reaction during the first infusion
of cetuximab. In rapid succession he developed pneumonia and
multi-organ failure and died several days after the first infusion of
cetuximab. Two patients died because of early disease progression.
One patient rapidly developed symptomatic brain metastases,
whereas two patients had rapid progression in extracerebral sites.
Toxicity
Haematological and non-haematological adverse events are
summarised in Table 2. Overall, 34 patients (65%; 95% CI,
50–76%) experienced grade 3/4 adverse events. One patient with-
drew consent during the first infusion cycle and is therefore exclu-
ded from detailed toxicity analyses. The most important grade 3/4
toxicities were: neutropenia 6%, febrile neutropenia 2%, thrombo-
cytopenia 2%, nausea 6%, diarrhoea 33%, sensory neuropathy 4%,
hand–foot-syndrome 6%, and skin-reactions 24%.
Response
In total, 46 patients were assessable for response according to
RECIST criteria. A total of 6 patients were not assessable (1 patient
died early because of the sequela of an infusion-related reaction, 1
withdrew consent, and 4 patients stopped therapy within the first
cycle because of toxicity and were switched to no treatment or
other second-line treatment without previous tumour assessment).
The overall response rate (ORR; complete response þ partial
response) was 65% (95% CI, 50–79%) including 4 complete and 26
partial responses (Table 3). In all, 18 responses have been formally
confirmed resulting in a confirmed ORR of 39%. Altogether, 17 out
of 22 patients with primary tumours located at the oesophago-
gastric junction had an objective response (77%) compared with
13 out of 24 patients (54%) with primary tumours located in the
stomach.
Table 1 Patient and tumour characteristics at baseline
Characteristic No of patients (n¼52) %
Age (years)
Median 63
Range 38–80
Gender
Male 39 75
Female 13 25
ECOG performance status
01 9 3 7
12 5 4 8
28 1 5
Disease status
Locally advanced 0 0
Metastatic 52 100
Metastatic sites
Lymph node 45 87
Liver 23 46
Lung 9 17
Peritoneum 16 31
Bone 4 8
Other 5 10
Site of the primary tumour
Oesophago-gastric junction 25 48
Stomach 27 52
No. of organs involved
11 0 1 9
22 0 3 9
422 2 4 2
Previous therapy
Chemotherapy (adjuvant) 12 23
Radiotherapy 3 6
Surgery 26 52
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
Table 2 Haematological and non-haematological toxicities (National
Cancer Institute Common Toxicity Criteria, Version 3.0)
No. of patients (%) (n¼51)
Toxicity Grade 1–2 Grade 3–4 Total
Haematological toxicity
Anaemia 42 (82) 0 (0) 42 (82)
Neutropenia 23 (45) 3 (6) 26 (51)
Febrile neutropenia — 3 (5) 3 (5)
Thrombocytopenia 15 (29) 1 (2) 16 (31)
Non-haematological toxicity
Diarrhoea 26 (51) 17 (33) 43 (84)
Nausea 28 (54) 3 (6) 31 (60)
Emesis 15 (29) 0 (0) 15 (29)
Skin toxicity 33 (65) 12 (24) 47 (89)
Sensory neuropathy 33 (65) 2 (4) 35 (69)
Hand–foot syndrome 16 (31) 3 (6) 19 (37)
Asthenia 30 (59) 5 (10) 35 (69)
Table 3 Anti-tumour activity (evaluable patients, n¼46)
Response according to RECIST No. of patients %
Overall response rate 30 65
Complete response 4 9
Partial response 26 57
Stable disease 8 17
Progressive disease 8 17
Abbreviation: RECIST¼Response Evaluation in Solid Tumours.
Cetuximab plus FUFOX in gastric cancer
F Lordick et al
502
British Journal of Cancer (2010) 102(3), 500–505 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sOS and TTP
At a median follow-up of 18 months, 44 out of 52 enrolled patients
(85%) presented with progressive disease. At the time of this
analysis, 18 patients (35%) are alive.
The median TTP was 7.6 months (95% CI: 5.0–10.1 months;
Figure 1A). The probability of remaining progression-free at 1 year
was 19%.
The median OS was 9.5 months (95% CI: 9.7–11.1 months;
Figure 1B). The 1-year survival rate for patients with metastatic
disease was 37%.
EGFR status and KRAS mutation analysis
Overall, 42 tumour blocks or slides were available for EGFR
analysis and were reviewed centrally at the Institute of Pathology,
Technische Universita ¨tM u ¨nchen. Immunohistochemical EGFR
detection was possible in 60% of these samples. No clear
association was found between the detection of EGFR and the
response rate (Table 4). Of the 32 samples that were analysed for
KRAS mutation, only one mutation, located in the exon 1 region of
the KRAS gene, was found.
Post-progression treatment
Second- or third-line chemotherapy was given to 13 out of 52
patients (25%), consisting mainly of irinotecan (7 patients) and
taxanes (3 patients). Three patients received an alternative
platinum–fluoropyrimidine-based regimen. Three patients under-
went secondary tumour resection in an attempt to achieve a
maximum tumour reduction.
DISCUSSION
Cetuximab, a monoclonal IgG1 antibody has been shown to
improve the activity of platinum-based chemotherapy (Vermorken
et al, 2008; Bokemeyer et al, 2009). Epidermal growth factor
receptor, the target of cetuximab, is overexpressed in gastric
cancer (Gamboa-Dominguez et al, 2004; Dragovich et al, 2006).
Overexpression of EGFR has, in some studies, been associated with
a poor prognosis underlining the significant role EGFR may have
in human gastric cancer biology. Therefore, it was considered of
value to investigate cetuximab in combination with platinum-
based combination therapy in patients with advanced gastric
cancer. The weekly FUFOX regimen was regarded as an appro-
priate chemotherapy backbone regimen, as a previous phase II
multicentre trial had shown encouraging activity of FUFOX in
patients with metastatic gastric cancer (Lordick et al, 2005).
The design of this phase II study defined an overall response
rate (partial and complete responses) of 30–50% as expected and
of 50% or more as being worth further investigation. Response
rates of the established chemotherapy doublet regimens used in
comparable patient populations have been reported to be below
30% in randomised trials, for example: 20% for cisplatinum and
5-FU in an EORTC study (Vanhoefer et al, 2000) and 25%
for cisplatin plus 5-fluororacil in the randomised TAX325 study
(Van Cutsem et al, 2006). Response rates for chemotherapy triplets
have been reported to be above 30% but below 50%, for example
46% for epirubicine plus cisplatin and 5-fluorouracil (Waters et al,
1999) and 37% for docetaxel plus cisplatin and 5-fluorouracil
(Van Cutsem et al, 2006). Therefore, we felt that an expected
response rate of 30–50% for a chemotherapy doublet plus one
biologically targeted agent (‘new triplet’) is an adequate assump-
tion. A response rate of 450% (alternative hypothesis) would be of
particular interest for further phase III testing of the new drug.
Treatment with cetuximab plus FUFOX-induced objective
tumour responses in 65% of treated patients, which was clearly
above the threshold for accepting the alternative hypothesis. It was
also 10% higher than the overall response rate that had been
observed in the previous FUFOX alone study (Lordick et al, 2005).
This comparison allows the cautious conclusion that cetuximab
may increase the activity of chemotherapy with a platinum
compound plus a fluoropyrimidine in advanced gastric cancer.
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Figure 1 Kaplan–Meier estimates of (A) time to progression (TTP) and
(B) overall survival (OS) among patients with metastatic gastric cancer
treated with cetuximab, oxaliplatin, folinic acid, and 5-fluorouracil (FUFOX).
Table 4 Clinical outcome according to EGFR immunohistochemistry
EGFR
detectable
EGFR non-
detectable
Overall response rate 54% 76%
Clinical benefit rate (CR, PR, and SD) 79% 82%
Median time to progression 7.0 months 9.4 months
Median overall survival 8.1 months 9.9 months
Abbreviations: CR¼complete response; EGFR¼epidermal growth factor receptor;
PR, partial response; SD¼stable disease.
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groups who have studied cetuximab in advanced gastric cancer.
Pinto et al (2007) were the first to study cetuximab in combination
with irinotecan and 5-fluorouracil in this setting and recorded
a response rate of 44% with a 95% CI ranging from 28 to 61%,
thus indicating the substantial activity of this regimen. The same
authors recently published the results of a phase II study
combining cetuximab with cisplatin and docetaxel in advanced
gastric cancer (Pinto et al, 2009). The observed objective response
rate of 41% (95% CI, 29–53) was judged to be higher than with
cisplatin and docetaxel alone. The TTP in Pinto’s first study was
particularly interesting as it approached a median of 8 months,
which is longer than that achieved with irinotecan and
5-fluorouracil alone (Pozzo et al, 2004; Dank et al, 2008). These
results are supported by the current study in which the median
TTP was found to be 7.6 months. A shorter TTP of median 5.5
months, together with a noteworthy response rate of 50%, was
reported in the first cetuximab–chemotherapy study published
from East Asia (Han et al, 2009).
The potentially enhanced anti-tumoural effects of chemotherapy
when combined with cetuximab in gastric cancer seen in these
clinical trials are not unexpected, given that data from preclinical
trials in EGFR-expressing gastric cancer cell lines and tumour
xenografts suggested an anti-tumour effect of cetuximab as a result
of different intracellular and immunological mechanisms (Hara
et al, 2008; Shimura et al, 2008; Patel et al, 2009). Moreover, one
recently described mechanism of resistance against cetuximab,
that is the activating mutation of the KRAS gene, seems to have a
very low prevalence in gastric cancer (Kim et al, 2003; Lee et al,
2003; Zhao et al, 2004). This finding has been confirmed in the
current study, wherein a KRAS mutation was found in only one
tumour sample.
This study revealed that cetuximab plus FUFOX is a feasible
regimen associated with the generally manageable toxicity.
However, the rate and the severity of observed side effects and
adverse events were higher than that reported with FUFOX alone.
The incidence of diarrhoea (33% grade 3/4), in particular, seemed
to be increased with the addition of cetuximab and the different
phenotypes of skin toxicities (24% grade 3/4) associated with
the use of anti-EGFR-directed drugs must also be taken into
consideration. The patients enrolled in this trial presented with a
high tumour load. All patients had metastatic disease, no patients
with locally advanced tumours were included, and almost 50% had
more than two organ systems involved. Compared with other
phase II studies like the FUFOX alone study published previously
(Lordick et al, 2005), patients presented with a poorer performance
status and many had been pretreated with adjuvant chemotherapy.
The poorer performance status and more advanced disease status
of patients included in this study is also reflected by the 60-day
mortality rate of 10% that was higher than in previously reported
phase II trials of the same group of authors (Lordick et al, 2005;
Lorenzen et al, 2007). This may explain the short duration of
treatment in a considerable number of patients. Tragically, one
patient died because of the sequelae of a severe infusion-related
drug reaction occurring during the first infusion of cetuximab.
This appalling event underlines the necessity of prophylactic
premedication with corticosteroids and antihistamines in patients
undergoing the first infusion with cetuximab and the uncondi-
tional need for continuous cardiorespiratory monitoring and
direct observation.
New biologically targeted agents are currently being investigated
in gastric cancer. The results of this study, together with Pinto
et al’s study published previously, encouraged us to initiate a
randomised, multinational, phase III study to investigate the value
of cetuximab in combination with platinum–fluoropyrimidine–
chemotherapy in stage IV gastric cancer.
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